Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yunke versus methotrexate for active rheumatoid arthritis
ChiCTR-IPR-14005684Phase 4Completed
- Sponsor
- Renji Hospital
- Start
- May 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of technetium-99m-methylene diphosphonate and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Renji Hospital. Primary endpoint: ACR20. Started May 2010; status: completed.
02
Drugs
technetium-99m-methylene diphosphonatemethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR-IPR-14005684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005684.